Ключевые слова
Как цитировать
Аннотация
В обзоре обобщены результаты экспериментальных, доклинических и клинических исследований, посвященных изучению эффективности комбинации интерлейкина 2 и ингибиторов контрольных иммунных точек. Представлены данные о проводимых в настоящее время зарегистрированных клинических исследованиях комбинации ингибиторов иммунных контрольных точек и препаратов на основе интерлейкина 2 и/или активированных этим цитокином эффекторов противоопухолевого иммунитета. Накопленные к настоящему времени экспериментальные и предварительные клинические данные свидетельствуют о перспективности этой стратегии иммунотерапии онкологических больных.
Библиографические ссылки
Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127-3132. DOI: 10.1200/JCO.2003.02.122
Motohashi S., Nagato K., Kunii N., et al. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunother. 2009;182:2492-2501. DOI: 10.4049/jimmunol.0800126
Zhao B., Zhang W., Yu D., Xu J., Wei Y Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(68):113105-113119. DOI: 10.18632/oncotarget.19373
Dudley M.E., Yang J.C., Sherry R., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233-5239. DOI: 10.1200/JCO.2008.16.5449
Нуриев Р.И., Караулов А.В., Киселевский М.В. Новые стратегии лечения пациентов с онкологическими заболеваниями: иммунотерапевтический подход. Иммунология. 2017. Т. 38. № 1. С. 39-48.
Шубина И.Ж., Бгюменберг А.Г., Волков С.М., Демидов Л.В., Киселевский М.В. Адоптивная иммунотерапия злокачественных новообразований. Вестник Российской академии медицинских наук. 2007. № 11. С. 9-15.
André F., Zielinski C.C. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. (2012) 23:vi46-51. DOI: 10.1093/annonc/mds195
Robinson TO., Schluns K.S. The potential and promise of IL-15 in immuno-oncogenic therapies. Immunol Lett. 2017;190:159-168. DOI: 10.1016/j.imlet.2017.08.010
Hanzly M., Aboumohamed A., Yarlagadda N., et al. High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience. Urology. 2014;83(5):1129-1134. DOI: 10.1016/j.urology.2014.02.005
Payne R., Glenn L., Hoen H., Richards B, Smith J.W., 2nd, Lufkin R, Crocenzi TS, Urba WJ, Curti BD. Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program. J Immunother cancer. 2014;2:2-13. DOI: 10.1186/2051-1426-2-13
Alva A., Daniels G.A., Wong M.K.K., Kaufman H.L. et al. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother. 2016; 65(12): 1533-1544. 2016 Oct 6. DOI: 10.1007/s00262-016-1910-x
Hanzly M., Aboumohamed A., Yarlagadda N., et al. High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience. Urology. 2014;83:1129-1134. DOI: 10.1016/j.urology.2014.02.005
McDermott D.F., Cheng S.C., Signoretti S., et al. The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2015 Feb 1;21(3):561-8. DOI: 10.1158/1078-0432.CCR-14-152
Smid M., Hoes M., Sieuwerts A.M., Sleijfer S., Zhang Y., Wang Y, et al. Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. Breast Cancer Res Treat. (2011) 128:23-30. DOI: 10.1007/s10549-010-1026-5
Blymenberg A.G., Kiselevski M.V., Gorbunova V.A., Volkov S.V., Kadagidze Z.G. Immunotherapy IL-2. Int. J. Gynecol. Cancer. 2002. 12. № 5. С. 70.
Титов К.С., Демидов Л.В., Киселевский М.В., Шубина И.Ж., Михайлова И.Н., Родионова Л.М., Тополь К.Ю., Синельников И.Е., Грицай А.Н. Внутриплевральная иммунотерапия интерлейкином-2 больных с метастатическим плевритом. Российский онкологический журнал. 2010. № 4. С. 20-22.
Kimura H., Yamaguchi Y.A. phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carci-noma.Cancer. 1997;80(1):42-49. PMID:. ISBN: 9210707
Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723, Topalian SL, Hodi FS, Brahmer JR, et al. Safety activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454. DOI: 10.1056/NEJMoa1200690
Curti B., Daniels G.A., McDermott D.F., Clark J.I., Kaufman H.L., Logan T.F. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. J Immunother Cancer. 2017;5(1):102. DOI: 10.1186/s40425-017-0307-5
Bauer K.R., Brown M., Cress R.D., Parise C.A., Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-nega-tive invasive breast cancer, the so-called triple-negative phenotype. cancer (2007) 109:1721-8. DOI: 10.1002/cncr.22618
Pillet A-H., Bugault F., Thèze J., Chakrabarti L.A., Rose T. A Programmed Switch from IL-15- to IL-2-dependent activation in human NK cells. J Immunol. (2009) 182:6267-77. DOI: 10.4049/jimmunol.0801933
Robinson TO., Schluns K.S. The potential and promise of IL-15 in immuno-oncogenic therapies. Immunol Lett. (2017) 190:159-68. DOI: 10.1016/j.imlet.2017.08.010
Wrangle J.M., Velcheti V., Patel M.R., Garrett-Mayer E., Hill E.G., Ravenel J.G., et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. (2018) 19:694-704. DOI: 10.1016/S1470-2045(18)30148-7
Xu C., Zhang Y., Alexander Rolfe P., Hernandez V.M., Guzman W., Kradjian G., et al. Combination therapy with NHS-muIL12 and avelumab (anti-PD-L1) enhances antitumor efficacy in preclinical cancer models. Clin Cancer Res. (2017) 23:5869-80. DOI: 10.1158/1078-0432.CCR-17-0483
Julia E.P., Amante A., Pampena M.B., Mordoh J., Levy E.M. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells Front Immunol. 2018; 9: 2140. DOI: 10.3389/fimmu.2018.02140
Kinter A.L., Godbout E.J., McNally J.P., Sereti I., Roby G.A., O'Shea M.A., Fauci A.S. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol. 2008;181(10):6738-46. DOI: 10.4049/jimmunol.181.10.6738
Чикилева И.О., Шубина И.Ж., Самойленко И.В., Караулов А.В., Киселевский М.В. Влияние антител к CTLA-4 и PD-1 на содержание их рецепторов мишеней. Медицинская иммунология, 2019, Т. 21, № 1, стр. 59-68.
Prieto P.A., Yang J.C., Sherry R.M., Hughes M.S., Kammula U.S., White D.E., Levy C.L., Rosenberg S.A., Phan G.Q. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18:2039-2047. DOI: 10.1158/1078-0432.CCR-11-1823
June C.H., Warshauer J.T., Bluestone J.A. Autoimmunity the Achilles'heel of cancer immunotherapy. Nat Med. 2017;23:540-547. DOI: 10.1038/nm.4321
Yang J.D., Sherry R.M., Steinberg S.M., Topalian S.L., Schwartzentruber D.J., Hwu P., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127-3132. DOI: 10.1200/JCO.2003.02.122
Klapper J.A., Downey S.G., Smith F.O., Yang J.C., Hughes M.S., Kammula U.S., Sherry R.M., Royal R.E., Steinberg S.M., Rosenberg S. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113:293-301. DOI: 10.1002/cncr.23552
Chow S., Galvis V., Pillai M., Leach R., Keene E., SpencerShaw A., Shablak A., Shanks J., Liptrot T, Thistlethwaite.F, Hawkins R.E. High-dose interleukin-2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome. J Immunother of. Cancer. 2016;4:67. DOI: 10.1186/s40425-016-0174-5
Alva A., Daniels G.A., Wong M.K.K., Kaufman H.L., Morse M.A., McDermott D.F., et al. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother. 2016;65:1533-1544. DOI: 10.1007/s00262-016-1910-x
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2020